Abstract | BACKGROUND: METHODS: RESULTS: A total of 4,020 (40%) received a GPI. Those receiving a GPI were more likely to be younger, be male, and undergo multivessel PCI. There was no interaction between treatment and GPI use for the primary efficacy and safety end points. Patients treated without GPI had a lower rate of definite stent thrombosis and higher rate of minor/major bleeding with ticagrelor compared with clopidogrel (P < .05), whereas there was no such difference with GPI (P interaction < .05). CONCLUSIONS: In patients with acute coronary syndrome undergoing early PCI, the efficacy and safety of ticagrelor as compared with clopidogrel were not modified by GPI use according to the primary efficacy and safety end point of the trial, although there were indications of greater benefit on definite stent thrombosis and more major or minor bleeding with ticagrelor in patients without (vs with) GPI treatment.
|
Authors | Yuichi J Shimada, Sameer Bansilal, Stephen D Wiviott, Richard C Becker, Robert A Harrington, Anders Himmelmann, Benjamin Neely, Steen Husted, Stefan K James, Hugo A Katus, Renato D Lopes, Ph Gabriel Steg, Robert F Storey, Lars Wallentin, Christopher P Cannon, PLATO Investigators |
Journal | American heart journal
(Am Heart J)
Vol. 177
Pg. 1-8
(Jul 2016)
ISSN: 1097-6744 [Electronic] United States |
PMID | 27297843
(Publication Type: Journal Article, Randomized Controlled Trial)
|
Copyright | Copyright © 2016 Elsevier Inc. All rights reserved. |
Chemical References |
- Antibodies, Monoclonal
- Immunoglobulin Fab Fragments
- Peptides
- Platelet Aggregation Inhibitors
- Platelet Glycoprotein GPIIb-IIIa Complex
- Purinergic P2Y Receptor Antagonists
- Tyrosine
- Clopidogrel
- Tirofiban
- Ticagrelor
- Adenosine
- Eptifibatide
- Ticlopidine
- Aspirin
- Abciximab
|
Topics |
- Abciximab
- Acute Coronary Syndrome
(therapy)
- Adenosine
(analogs & derivatives, therapeutic use)
- Aged
- Antibodies, Monoclonal
(therapeutic use)
- Aspirin
(therapeutic use)
- Cardiovascular Diseases
(mortality)
- Clopidogrel
- Drug Therapy, Combination
- Drug-Eluting Stents
- Eptifibatide
- Female
- Graft Occlusion, Vascular
(epidemiology)
- Hemorrhage
(chemically induced)
- Humans
- Immunoglobulin Fab Fragments
(therapeutic use)
- Male
- Middle Aged
- Myocardial Infarction
(epidemiology)
- Peptides
(therapeutic use)
- Percutaneous Coronary Intervention
- Platelet Aggregation Inhibitors
(therapeutic use)
- Platelet Glycoprotein GPIIb-IIIa Complex
(antagonists & inhibitors)
- Purinergic P2Y Receptor Antagonists
(therapeutic use)
- Stroke
(epidemiology)
- Thrombosis
(epidemiology)
- Ticagrelor
- Ticlopidine
(analogs & derivatives, therapeutic use)
- Tirofiban
- Tyrosine
(analogs & derivatives, therapeutic use)
|